fig6

Figure 6. (A) Engineered MEVs for AD. Schematic illustration of the construction of MEVs to deliver BACE1 mRNA with targeting and anti-AD effects^[83]. Copyright 2011 Springer Nature. (B) Engineered MEVs for PD. Schematic illustration of the construction of MEVs to deliver catalase mRNA with targeting and anti-PD effects^[81]. Copyright 2018 Springer Nature. (C) Engineered MEVs for ischemic stroke.Schematic illustration of the construction of MEVs to deliver catalase miR-124 with targeting and anti-ischemic stroke effects^[124]. Copyright 2017 Elsevier. MEVs: Mammalian extracellular vesicles. AD: Alzheimer’s disease. PD: Parkinson’s disease. Significance of finding was defined as follows: not significant, ^nsP > 0.05; ^*P < 0.05; ^**P < 0.01; ^***P < 0.001.